Skip to main content

bimatoprost

Generic: BIMATOPROST·Brand: BIMATOPROST, DURYSTA, Durysta, LATISSE, LUMIGAN, ZOLYMBUS

bimatoprost: sourced relationships with 1 company · 2 clinical trials tracked · 3 FDA decisions.

bimatoprost evidence translation

What we can confirm

3 FDA records · 2 tracked trials

What it means

Source-backed records connect bimatoprost to ABBV; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could bimatoprost → ABBV affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors

Related indications

GlaucomaOcular Hypertension
Dated Pipeline Records (1)
CompanyDated record stage
AbbVie Inc. (ABBV)
Reported 2008-12-24 · Current development: unknownSource
Approved
Clinical Trial Registry Records (2)

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

NCT07217678Registry updated 2026-03-05·Phase 4
Recruiting

Primary endpoint: Change in Caspase-1 mRNA Expression Following Durysta Injection

Interventionalopen20 targetStarted 2026-02Completion 2028-011 site · United StatesUniversity of Miami

A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122Registry updated 2026-09-03·Phase 2·OCUL
Completed

Primary endpoint: IOP Changes From Baseline in the Study Eye

InterventionalRandomizeddouble83 enrolledStarted 2022-03Completion 2025-0130 sites · United StatesOcular Therapeutix, Inc.
FDA Decisions3 records
Approval(ABBV)FDA ↗
NDA211911Type 3 - New Dosage FormStandardOphthalmicImplant
Approval1 INDICATIONS AND USAGE LUMIGAN ® (bimatoprost ophthalmic solution) 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. LUMIGAN ® 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 1 )(ABBV)FDA ↗
NDA022184Type 5 - New Formulation or New ManufacturerStandardOphthalmicSolution/Drops
Approval(ABBV)FDA ↗
NDA022369Type 5 - New Formulation or New ManufacturerPriorityTopicalSolution/Drops

Frequently asked questions

Which companies have sourced relationships with bimatoprost?

bimatoprost has dated SEC/FDA relationship records for AbbVie Inc..

How many clinical trials involve bimatoprost?

BioSniper tracks 2 clinical trials involving bimatoprost.

What is bimatoprost's latest FDA decision?

The most recent tracked FDA decision for bimatoprost is Approval, dated March 4, 2020.